Evidence map›Paper›PMID 40360648›Full record

SynthesisScientific reports2025

Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials.

Shike Lin, Yan Deng, Jing Huang, Meiyan Li, Suren Rao Sooranna, Minzhen Qin, Bing Tan

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shike LinOffice of Science and Technology, Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Yan DengDepartment of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China.
Jing HuangDepartment of Pharmacy, Affiliated Hospital of Youjiang Medical University for Nationalities, No.18#, Zhongshan 2nd Road, Baise, 533000, Guangxi, China.
Meiyan LiNational Immunological Laboratory of Traditional Chinese Medicine, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Suren Rao SoorannaDepartment of Metabolism, Digestion and Reproduction, Imperial College London, 369 Fulham Road, London, SW10 9NH, UK.
Minzhen QinDepartment of Gastroenterology, Baise People's Hospital, Baise, 533000, Guangxi, China. qinminzhen@ymun.edu.cn.
Bing TanDepartment of Pharmacy, Affiliated Hospital of Youjiang Medical University for Nationalities, No.18#, Zhongshan 2nd Road, Baise, 533000, Guangxi, China. tanbing@ymun.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) when compared to metformin and placebo in the management of body weight, glucose homeostasis and hormone levels in women polycystic ovary syndrome (PCOS). A systematic search of "PubMed", "EMBASE", "Cochrane Library", "Web of Science" and "Google Scholar" was conducted up to October 2024 for randomized controlled trials involving adult women with PCOS treated with GLP-1RAs compared to metformin or placebo. The primary outcomes were changes in body mass index (BMI), body weight, waist circumference (WC), waist-to-hip ratio (WHR) and abdominal girth (AG). Secondary outcomes included glucose homeostasis (fasting glucose, fasting insulin, OGTT results and HOMA-IR), hormone levels (DHEAS, SHBG, total and free testosterone and FAI), lipid profiles (total cholesterol, HDL, LDL and triglycerides) and safety. GLP-1RAs significantly reduced BMI, body weight, WC, WHR and AG (P < 0.0001 in all cases). For glucose homeostasis, GLP-1RAs significantly reduced fasting insulin, glucose level at 2 h after OGTT, and HOMA-IR. There was also a reduction in HDL. All the other parameters measured were unchanged. In addition, GLP-1RAs increased nausea (P = 0.02), vomiting (0.04) and dizziness (0.03). GLP-1RAs effectively reduced body weight, BMI and insulin resistance in patients with PCOS, although they were accompanied by nausea, vomiting and dizziness. Further studies are needed to explore their long-term effects on glucose homeostasis and lipid profiles.

Indexed as

Body WeightGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsPolycystic Ovary SyndromeAdultBlood GlucoseBody Mass IndexFemaleHumansInsulinMetforminRandomized Controlled Trials as TopicTreatment OutcomeBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinMetforminAnthropometric measurementGLP-1 receptor agonistsGlucose homeostasisMeta-analysis of RCTsMetabolic outcomesPolycystic ovary syndrome

Identifiers

PMID40360648
PMCPMC12075827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.